Evidence map›Paper›PMID 41485914›Full record

ArticleInternal medicine (Tokyo, Japan)2026

An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.

Yoko Nakanishi, Masaki Ri, Shiori Mizutani, Nozomi Nishitarumizu, Yuki Furukawa, Yukiyasu Kato, Hirokazu Sasaki, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yoko NakanishiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Masaki RiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Shiori MizutaniDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Nozomi NishitarumizuDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Yuki FurukawaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Yukiyasu KatoDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Hirokazu SasakiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Arisa AsanoDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Shiori KinoshitaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Tomotaka SuzukiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Tomoko NaritaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Shohei MizunoDivision of Hematology, Aichi Medical University, Japan.
Hiroyuki MiyashitaDepartment of Hematology, Yokkaichi Municipal Hospital, Japan.
Takaomi SandaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Takanori NanriDepartment of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Japan.
Hirokazu KomatsuDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report four patients who were unable to receive idecabtagene vicleucel (ide-cel) due to disease progression, despite undergoing leukapheresis within specification. The median age of the patients was 70 (range, 68-77) years old. Two patients had nonsecretory subtypes at the diagnosis. The median number of prior therapy lines was 4.5 (range, 4-6), and 3 patients were penta-refractory. All patients were refractory to the latest treatment. The median time from apheresis to ide-cel cancellation was 44.5 (range: 24-71) days. Our findings suggest that the nonsecretory subtype and penta-refractoriness may increase the risk of treatment discontinuation. Early ide-cel application and improved bridging therapy are warranted to enhance treatment completion after leukapheresis.

Indexed as

LeukapheresisMultiple MyelomaAgedDisease ProgressionFemaleHumansMaleBCMA-CARnon-secretory typepenta-refractory

Identifiers

PMID41485914
PMCPMC13521637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.